Agenus stock doubles as biotech narrows Phase 3 bet

Agenus is redirecting its Phase 3 colon-cancer strategy.

The biotech institution said connected July 13 that it volition halt providing fiscal enactment for its BATTMAN survey and marque ROBBIN, a planned Phase 3 proceedings of BOT+BAL earlier colon-cancer surgery, its cardinal improvement priority.

The displacement is backed by a backstage placement expected to supply astir $85 cardinal upfront. Agenus could person different $255 cardinal if accompanying warrants are afloat exercised, bringing imaginable gross proceeds to $340 million.

Investors rewarded the operation of a narrower objective strategy and caller capital. Agenus (AGEN) shares were precocious trading astatine $6.46, up 93.1% from July 10's close, according to Yahoo Finance, aft reaching $8.70 earlier successful the session.

The financing gives the institution $85 cardinal present and a imaginable way to the remainder done warrants, a favoritism that shapes some the accidental and the dilution hazard for shareholders.

Agenus chooses ROBBIN implicit BATTMAN

Agenus plans to nonstop the financing toward ROBBIN, a randomized planetary Phase 3 survey of botensilimab positive balstilimab, known arsenic BOT+BAL, successful patients with high-risk Stage II and Stage III microsatellite-stable colon cancer.

The proceedings is expected to enroll astir 850 patients. It volition comparison patients who person BOT+BAL earlier country with patients who proceed straight to surgery, with event-free endurance serving arsenic the superior endpoint.

The institution expects the archetypal ROBBIN diligent to beryllium dosed successful the archetypal 4th of 2027. Interim pathologic-response information are expected successful the 2nd fractional of that year, followed by an interim event-free-survival investigation successful 2029 and a last investigation successful 2030.

Agenus is making country for that programme by discontinuing fiscal enactment for BATTMAN, its Phase 3 proceedings successful patients with late-line metastatic MSS colorectal cancer. The institution said it volition proceed gathering its obligations to patients already receiving treatment.

Our program to prioritize neoadjuvant BOT+BAL successful MSS colon crab reflects some the spot of the emerging objective evidence.

The determination leaves Agenus with a much concentrated Phase 3 strategy. Rather than financing 2 late-stage paths astatine once, the institution is placing much of its superior down the earlier-treatment mounting it considers its higher-value opportunity.

Related: Jensen: How to Play Agenus Using Options

Agenus gets upfront currency with much tied to warrants

The upfront information of the transaction is expected to make astir $85 cardinal earlier expenses.

That magnitude provides contiguous alleviation for a institution that ended the archetypal 4th with $35 cardinal successful currency and currency equivalents. Agenus reported astir $51.8 cardinal successful currency payments during the quarter, though it said immoderate of those costs were tied to one-time obligations and manufacturing investments.